This research was supported in part by the Intramural Research Program of the NCI, NIH, Medical Research Fund Tirol (MFF71, MFF153), the Austrian Science Fund (FWF J1901-MED, J2112-MED, P16990-B05), the European Cooperation in Science and Technology (COST Action BM0903)”
Systemic retinoids in the management of ichthyoses and related skin types
Version of Record online: 5 FEB 2013
© 2013 Wiley Periodicals, Inc.
Volume 26, Issue 1, pages 26–38, January/February 2013
How to Cite
DiGiovanna, J. J., Mauro, T., Milstone, L. M., Schmuth, M. and Toro, J. R. (2013), Systemic retinoids in the management of ichthyoses and related skin types. Dermatologic Therapy, 26: 26–38. doi: 10.1111/j.1529-8019.2012.01527.x
- Issue online: 5 FEB 2013
- Version of Record online: 5 FEB 2013
- Intramural Research Program of the NCI, NIH, Medical Research Fund Tirol. Grant Numbers: MFF71, MFF153
- Austrian Science Fund. Grant Numbers: J2112-MED, P16990-B05
- European Cooperation in Science and Technology. Grant Number: COST Action BM0903
The term retinoid includes both natural and synthetic derivatives of vitamin A. Retinoid-containing treatments have been used since ∼1550BC by the early Egyptians. Treatment of ichthyosiform disorders with retinoids dates back at least to the 1930s. Early use of high-dose vitamin A demonstrated efficacy, but because vitamin A is stored in the liver, toxicity limited usefulness. Interest turned to synthetic retinoids in an effort to enhance efficacy and limit toxicity. Acetretin, isotretinoin and, in the past etretinate, have provided the most effective therapy for ichthyosiform conditions. They have been used for a variety of ages, including in newborns with severe ichthyosis and for decades in some patients. Careful surveillance and management of mucous membrane, laboratory, skeletal, and teratogenic side effects has made systemic retinoids the mainstay of therapy for ichthyosis and related skin types.